Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease
- PMID: 11116070
- DOI: 10.1161/01.atv.20.12.2670
Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease
Abstract
High density lipoproteins (HDLs) and their subspecies play a role in the development of coronary heart disease (CHD). HDL subpopulations were measured by 2-dimensional nondenaturing gel electrophoresis in 79 male control subjects and 76 male CHD patients to test the hypothesis that greater differences in apolipoprotein (apo)A-I-containing HDL subpopulations would exist between these 2 groups than for traditional lipid levels. In CHD subjects, HDL cholesterol (HDL-C) was lower (-14%, P<0.001), whereas total cholesterol and the low density lipoprotein cholesterol/HDL-C ratio were higher (9% [P:<0.05] and 21% [P:<0.01], respectively) compared with control levels. No significant differences were found for low density lipoprotein cholesterol, triglyceride, and apoA-I levels. In CHD subjects, there were significantly (P:<0.001) lower concentrations of the large lipoprotein (Lp)A-I alpha(1) (-35%), pre-alpha(1) (-50%), pre-alpha(2) (-33%), and pre-alpha(3) (-31%) subpopulations, whereas the concentrations of the small LpA-I/A-II alpha(3) particles were significantly (P:<0.001) higher (20%). Because alpha(1) was decreased more than HDL-C and plasma apoA-I concentrations in CHD subjects, the ratios of HDL-C to alpha(1) and of apoA-I to alpha(1) were significantly (P:<0.001) higher by 36% and 57%, respectively, compared with control values. Subjects with low HDL-C levels (</=35 mg/dL) have different distributions of apoA-I-containing HDL subpopulations than do subjects with normal HDL-C levels (>35 mg/dL). Therefore, we stratified participants according to HDL-C concentrations into low and normal groups. The differences in lipid levels between controls and HDL-C-matched cases substantially decreased; however, the significant differences in HDL subspecies remained. Our research findings support the concept that compared with control subjects, CHD patients not only have HDL deficiency but also have a major rearrangement in the HDL subpopulations with significantly lower alpha(1) and pre-alpha(1-3) (LpA-I) and significantly higher alpha(3) (LpA-I/A-II) particles.
Similar articles
-
Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease.Atherosclerosis. 2001 May;156(1):217-25. doi: 10.1016/s0021-9150(00)00643-2. Atherosclerosis. 2001. PMID: 11369017
-
ApoA-IHelsinki (Lys107-->0) associated with reduced HDL cholesterol and LpA-I:A-II deficiency.Arterioscler Thromb Vasc Biol. 1995 Sep;15(9):1294-306. doi: 10.1161/01.atv.15.9.1294. Arterioscler Thromb Vasc Biol. 1995. PMID: 7670941
-
Relationship between low-density lipoprotein size and apolipoprotein A-I-containing particles: the ECTIM study.Eur J Clin Invest. 1997 Mar;27(3):242-7. doi: 10.1046/j.1365-2362.1997.1000644.x. Eur J Clin Invest. 1997. PMID: 9088861
-
Increasing apoA-I production as a target for CHD risk reduction.Nutr Metab Cardiovasc Dis. 2007 Oct;17(8):616-28. doi: 10.1016/j.numecd.2007.05.001. Epub 2007 Aug 20. Nutr Metab Cardiovasc Dis. 2007. PMID: 17703927 Review.
-
The relationship between high density lipoprotein subclass profile and plasma lipids concentrations.Lipids Health Dis. 2010 Oct 17;9:118. doi: 10.1186/1476-511X-9-118. Lipids Health Dis. 2010. PMID: 20950490 Free PMC article. Review.
Cited by
-
FAMP, a novel apoA-I mimetic peptide, suppresses aortic plaque formation through promotion of biological HDL function in ApoE-deficient mice.J Am Heart Assoc. 2013 May 24;2(3):e000048. doi: 10.1161/JAHA.113.000048. J Am Heart Assoc. 2013. PMID: 23709562 Free PMC article.
-
Effects of dietary components on high-density lipoprotein measures in a cohort of 1,566 participants.Nutr Metab (Lond). 2014 Sep 15;11(1):44. doi: 10.1186/1743-7075-11-44. eCollection 2014. Nutr Metab (Lond). 2014. PMID: 25264450 Free PMC article.
-
Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity.J Lipid Res. 2017 Sep;58(9):1869-1883. doi: 10.1194/jlr.M077925. Epub 2017 Jul 12. J Lipid Res. 2017. PMID: 28701354 Free PMC article.
-
High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol.Clin Chem. 2010 Jul;56(7):1128-37. doi: 10.1373/clinchem.2009.139931. Epub 2010 May 28. Clin Chem. 2010. PMID: 20511449 Free PMC article.
-
Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study.Circ Res. 2016 Jan 8;118(1):73-82. doi: 10.1161/CIRCRESAHA.115.306223. Epub 2015 Dec 1. Circ Res. 2016. PMID: 26628614 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous